Dear All (wonkish but stick with it … I’m going to try very hard to de-wonk it),
In an absolutely terrifying paper and technical report in today’s issue of Science, we are introduced in detail to the concept of “mirror” bacteria in which all chiral elements of the bacterium are replaced by their enantiomeric counterparts. And if that’s completely unintelligible to you, please stick with me and read just a bit further — you really will want to understand this. To get us started, here are the links and ideas you need:
- The 4-page article itself: Adamala KP et al., “Confronting risks of mirror life.” Science 2024, DOI: 10.1126/science.ads9158.
- The 299-page technical report that accompanies the article: K. P. Adamala et al., “Technical report on mirror bacteria: Feasibility and risks” (Stanford Digital Repository, 2024); https://doi.org/10.25740/cv716pj4036.
- A version of the article’s text that is deeply cross-referenced into the full technical report.
- The Mirror Biology Dialogues Fund (MBDF) that has been created “to advance a global discussion to chart the path forward for mirror biology research.”
- General articles
- An informative introductory-level article entitled “Mirror Life” from Wikipedia that both covers the scientific idea and also provides a nice summary of mirror image stories from popular fiction.
- (12 Dec 2024 addendum): An outstanding long-read at a medium technical level: McCarty N and Moorhouse F: “The Dangers of Mirror Life”, https://www.asimov.press/p/mirror-life.
- 18 Jan 2025 addendum: “Opinion: Reflecting on the Risks of ‘Mirror Life’” dated 16 Jan 2025 is a good short summary of the concepts.
- Some words that matter in following the story:
- Chiral / Chirality: An object is chiral (or has chirality) if it can be distinguished from its mirror image. Your left and right hands are chiral.
- Enantiomer: Each object of a mirror-image chiral pair is called an enantiomer. Your left and right hands are enantiomers.
- Racemic mixture (or racemate): A 50-50 mixture of the enantiomers of a chiral pair. The clapping left and right hands of the audience are a racemic mixture.
- Achiral: An object is achiral (NOT chiral) if it cannot be distinguished from its mirror image. A solid white sphere is achiral.
- Chiral / Chirality: An object is chiral (or has chirality) if it can be distinguished from its mirror image. Your left and right hands are chiral.
OK, so what’s going on here? What is a mirror bacterium? The core concept begins with understanding that most molecules have a natural property that can be called “handedness” or chirality. Your left and right hands are great example of this. Further, think about a pair of gloves … the left glove won’t work very well (if at all) on your right hand.
Extending this a bit, it turns out that all living things on our lovely planet have agreed to use a consistent set of choices when molecules are sufficiently complex to be chiral. All proteins and all DNA/RNA strands use the same set of choices for their underlying amino acids and nucleotides. The opposite chirality would have worked, but it’s not what was chosen. (12 Dec 2024 addendum: The origins of our planetary agreement on homochirality are unknown, but if you are curious you can see Ozturk et al. (DOI: 10.1126/sciadv.adg8274) for a “prebiotically plausible way of achieving system-level homochirality from completely racemic starting materials, in a shallow-lake environment on early Earth where sedimentary magnetite deposits are expected to be common.” So there!)
A reasonable parallel would the concept of left-hand vs. right-hand traffic. Most of the world drives on the right … but the mirror image of driving on the left works just fine with a little practice (as I learned while living in the UK some years ago).
And that (drum roll) brings us at last to the idea of a mirror bacterium (or organism). If you could replace every chiral molecule in an E. coli with its enantiomer, you’d have a mirror E. coli. If put in a growth medium that contained achiral simple sugars as its carbon source, it would grow and divide normally.
So what’s the fuss? Why is this report creating such news? Although the idea of mirror life is known (at least to sci-fi fans), the potential to actually make a mirror organism has gone from speculative fiction to the possibility of near-term reality based (in particular, but not exclusively) on work exploring ways to make non-mirror organisms from basic chemical building blocks (see this ACS 2021 article for a very deep dive). The ability to actually do this is still at least a decade away, but it is coming … and once we can make a normal (non-mirror) bacterium from scratch, then making a mirror version would also be possible.
And with this, we come to the point of the paper and technical report in Science: All life on earth is in balance (even apex predators have each other as predators) but mirror bacteria would interact with existing life in profoundly different ways from non-mirror bacteria. The mirror bacteria would have many advantages that would mean that the mirror bacteria could easily come to dominate the global ecosystem:
- The natural innate immune defenses that all living things possess are designed to work against pathogens of the agreed (standard) chirality. A mirror bacterium might go unscathed.
- Similarly, adaptive immunity (e.g., the antibodies you make when you get vaccinated) will usually have a chiral nature and might well not work vs. a mirror bacterium.
- We might be able to develop vaccines for the mirror bacterium, but that would be a new vaccine.
- Natural predators of bacteria (bacteriophage and the protists that prey on bacteria) would be ineffective vs. mirror bacteria.
- Many antibiotics are chiral and would be ineffective vs. mirror bacteria.
- A handful of achiral (or racemic) antibiotics would still work: sulfas, quinolones, metronidazole, nitrofurantoin, and trimethoprim.
- But we’d lose the penicillins, the cephalosporins, the aminoglycosides, the tetracyclines, vancomycin, linezolid, and others.
- We could directly synthesize the mirror version of some compounds (e.g., linezolid) as it is readily made by direct synthesis.
- But anything that starts with a natural product (a large molecule made by bacteria or yeast; vancomycin would be an example) would be very hard to convert to a mirror form.
Or as the authors note, “We cannot rule out a scenario in which a mirror bacterium acts as an invasive species across many ecosystems, causing pervasive lethal infections in a substantial fraction of plant and animal species, including humans.”
Ugh! I encourage you to read the paper and the technical report for more details, but hopefully this paints the picture with clarity: Pandora’s Box for real!
What’s to be done? The authors get us started with these arguments. Note in particular the call for public conversation — the accompanying Mirror Biology Dialogue Fund (MBDF) website gives an initial view on how those conversations would be organized:
- “Unless compelling evidence emerges that mirror life would not pose extraordinary dangers, we believe that mirror bacteria and other mirror organisms, even those with engineered biocontainment measures, should not be created.
- “We therefore recommend that research with the goal of creating mirror bacteria not be permitted, and that funders make clear that they will not support such work.
- …
- “We believe that there is a productive path ahead in which a range of stakeholders collaboratively consider the risks from mirror life and develop appropriate governance without unnecessarily impeding scientific research.
- “Drawing inspiration from the Tianjin Biosecurity Guidelines and other relevant frameworks, we invite the global research community, policy-makers, research funders, industry, civil society, and the public to join this discussion.
- “To facilitate greater understanding of the risks associated with mirror life and further progress on governance, we plan to convene discussions on these topics in 2025.”
Nice ideas … but can we really stop this speeding train? At the very least, the science is still some years from reality and (provided we don’t delay) there’s time for the AMR development community to develop adequate responses: The current crisis of antimicrobial resistance (AMR) that has developed from the natural emergence of superbugs already threatens health worldwide and this report shows that mirror bacteria would sharply accelerate this crisis.
While hoping to keep this Pandora’s Box closed as long as possible, we should prepare for the day that mirror bacteria become a reality — and perhaps this would help us address the AMR crisis that is already afoot.
Critically, we have lamented in prior newsletters the lengthening R&D timelines for new antibacterial agents (e.g., the 30 June 2020 newsletter discussing Dheman et al., FDA’s analysis of 40 years of antibacterial development). The current typical time lags of a decade or more from start to approval would be much too slow to be an effective response: we really should start now to develop dramatically accelerated pathways for discovery, development, and manufacturing of innovative antimicrobials.
Yow! Terrifying, no? Put on your thinking caps. We’ll be talking about this again.
Meditatively yours, –jr
John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.
- NIAID’s RFA-AI-24-069 is a notice of funding opportunity (NOFO) soliciting applications to establish Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). The CAPT-CEPs will focus on developing preclinical assays, tools, and models for robust phage therapy research and development (R&D) and advancing phage clinical research. Applications are due by 28 Jan 2025; letters of intent must be received 30 days prior to the due date. See also the 23 Oct 2024 newsletter about the RFA for a discussion of issues with developing phage-based products.
- The 2026 NIAID DMID Omnibus Broad Agency Announcement (HHS-NIH-NIAID-BAA2025-1) seeks applications in its Research Area 001 for (i) therapeutics for bacterial and fungal infections, (ii) vaccines for bacterial infections, and in vitro diagnostics for fungal pathogens. Applications are due by 21 Feb 2025. See also the 26 Nov 2024 newsletter discussing the BAA.
- ENABLE-2 has continuously open calls for both its Hit-to-Lead program as well as its Hit Identification/Validation incubator. Applicants must be academics and non-profits in Europe due to restrictions from the funders. Applications are evaluated in cycles … see the website for details on current timing for reviews.
- CARB-X has open calls at intervals that span four areas: (i) Therapeutics for Gram-Negatives, (ii) Prevention for Invasive Disease, (iii) Diagnostics for Neonatal Sepsis, and (iv) Proof-Of-Concept for Diagnosing Lower-Respiratory-Tract Infections. See this 6 Mar 2024 newsletter for a discussion of the call and go here for the CARB-X webpage on the call. There are multiple opportunities to submit — see the CARB-X webpage for details.
- BARDA’s long-running BAA (Broad Agency Announcement) for medical countermeasures (MCMs) for chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases is now BAA-23-100-SOL-00004 and offers support for both antibacterial and antifungal agents (as well as antivirals, antitoxins, diagnostics, and more). Note especially these Areas of Interest: Area 3.1 (MDR Bacteria and Biothreat Pathogens), Area 3.2 (MDR Fungal Infections), and Area 7.2 (Antibiotic Resistance Diagnostics for Priority Bacterial Pathogens). Although prior BAAs used a rolling cycle of 4 deadlines/year, the updated BAA released 26 Sep 2023 has a 5-year application period that ends 25 Sep 2028 and is open to applicants regardless of location: BARDA seeks the best science from anywhere in the world! See also this newsletter for further comments on the BAA and its areas of interest.
- HERA Invest was launched August 2023 with €100 million to support innovative EU-based SMEs in the early and late phases of clinical trials. Part of the InvestEU program supporting sustainable investment, innovation, and job creation in Europe, HERA Invest is open for application to companies developing medical countermeasures that address one of the following cross-border health threats: (i) Pathogens with pandemic or epidemic potential, (ii) Chemical, biological, radiological and nuclear (CBRN) threats originating from accidental or deliberate release, and (iii) Antimicrobial resistance (AMR). Non-dilutive venture loans covering up to 50% of investment costs are available. A closing date is not posted insofar as I can see — applications are accepted on a rolling basis; go here for more details.
- The AMR Action Fund is open on an ongoing basis to proposals for funding of Phase 2 / Phase 3 antibacterial therapeutics. Per its charter, the fund prioritizes investment in treatments that address a pathogen prioritized by the WHO, the CDC and/or other public health entities that: (i) are novel (e.g., absence of known cross-resistance, novel targets, new chemical classes, or new mechanisms of action); and/or (ii) have significant differentiated clinical utility (e.g., differentiated innovation that provides clinical value versus standard of care to prescribers and patients, such as safety/tolerability, oral formulation, different spectrum of activity); and (iii) reduce patient mortality. It is also expected that such agents would have the potential to strongly address the likely requirements for delinked Pull incentives such as the UK (NHS England) subscription pilot and the PASTEUR Act in the US. Submit queries to contact@amractionfund.com.
- INCATE (Incubator for Antibacterial Therapies in Europe) is an early-stage funding vehicle supporting innovation vs. drug-resistant bacterial infections. The fund provides advice, community, and non-dilutive funding (€10k in Stage I and up to €250k in Stage II) to support early-stage ventures in creating the evidence and building the team needed to get next-level funding. Details and contacts on their website (https://www.incate.net/).
- These things aren’t sources of funds but would help you develop funding applications
- AiCuris’ AiCubator offers incubator support to very early stage projects. Read more about it here.
- The Global AMR R&D Hub’s dynamic dashboard (link) summarizes the global clinical development pipeline, incentives for AMR R&D, and investors/investments in AMR R&D.
- Diagnostic developers would find valuable guidance in this 6-part series on in vitro diagnostic (IVD) development. Sponsored by CARB-X, C-CAMP, and FIND, it pulls together real-life insights into a succinct set of tutorials.
- In addition to the lists provided by the Global AMR R&D Hub, you might also be interested in my most current lists of R&D incentives (link) and priority pathogens (link).
John’s Top Recurring Meetings
Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers are the AMR Conference and the ASM-ESCMID conference. Hope to see you there!
- 25-26 February 2025 (Basel, Switzerland): The 9th AMR Conference 2025. Go here to register!
- 11-15 April 2025 (Vienna, Austria): ESCMID Global 2025, the annual meeting of the European Society for Clinical Microbiology and Infectious Diseases. Go here for details.
- (no date as yet) 2025 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. Go here to see details of the outstanding 2024 meeting!
- 19-22 Oct 2025 (Georgia, USA): IDWeek 2025, the annual meeting of the Infectious Diseases Society of America. Details pending; go here for the general meeting website.
Upcoming meetings of interest to the AMR community:
- 23 Jan 2025 (virtual, 1700-1830 CET / 1100-1230 EST): GARDP REVIVE webinar entitled “The importance of chemical synthesis for antimicrobial R&D.” Go here to register.
- 28-29 Jan 2025 (online and in-person, Washington, DC): PACCARB (US Presidential Advisory Council on Combatting Antimicrobial Resistant Bacteria): This particular meeting of PACCARB is unusually important as it will seek (i) public input into NAP for CARB 2025-2030 and (ii) work to sustain the momentum regarding the commitments at the High-Level Meeting on AMR at the 2024 UN General Assembly (UNGA HLM AMR). Go to http://hhs.gov/paccarb for details and to register.
- 4-5 Feb 2025 (online, 1-5p GMT timing on both days): Antimicrobial Chemotherapy Conference by GARDP and BSAC in collaboration with CEPID-ARIES and Fiocruz. Now in its 6th year, the free program offers a good review of antimicrobial R&D, ranging from drug discovery to preclinical and clinical activities. Go here to register; the abstract deadline is 15 Nov 2024.
- [NEW] 5 Feb 2025 (The Spine, Liverpool): BioInfect 2025, Bionow’s annual north of England meeting for AMR researchers and industry professionals. The agenda includes a keynote lecture from Erin Duffy, Chief of Research & Development, CARB-X. Go here to register.
- 25-26 February 2025 (Basel, Switzerland): The 9th AMR Conference 2025. See list of Top Recurring meetings, above.
- 27 Feb 2025 (virtual, 1700-1830 CET / 1100-1230 EST): GARDP REVIVE webinar entitled “In vitro and in vivo correlations for prediction of human pharmacokinetics and dose of antimicrobials.” Go here to register.
- 11-15 April 2025 (Vienna, Austria): ESCMID Global 2025, the annual meeting of the European Society for Clinical Microbiology and Infectious Diseases. See Recurring Meetings list, above.
- 19-22 Oct 2025 (Georgia, USA): IDWeek 2025, the annual meeting of the Infectious Diseases Society
- 11-15 April 2025 (Vienna, Austria): ESCMID Global 2025. See list of Top Recurring meetings, above.
- 30 June-1 July 2025 (virtual and in Washington, DC): BID2025: BARDA Industry Days — Enhancing Health Security With a Sustainable Future. BID provides the opportunity to discuss U.S. government medical countermeasure (MCM) priorities, provide the private sector an informal opportunity to interact with BARDA and ASPR teams, and identify potential areas of collaboration in the field of MCM research and development. Go here for details.
- 19-22 Oct 2025 (Georgia, USA): IDWeek 2025. See list of Top Recurring meetings, above.
- 11-19 Oct 2025 (Annecy, France, residential in-person program): ICARe (Interdisciplinary Course on Antibiotics and Resistance) … and 2025 will be the 9th year for this program. Patrice Courvalin orchestrates content with the support of an all-star scientific committee and faculty. The resulting soup-to-nuts training covers all aspects of antimicrobials, is very intense, and routinely gets rave reviews! Seating is limited, so mark your calendars now if you are interested. Applications should open ~March 2025 — go here for more details.
- OpenWHO: “Antimicrobial Resistance in the environment: key concepts and interventions.” Per the webpage for the course, it will teach you “…why addressing AMR in the environment is essential and gain insights into how action can be taken to prevent and control AMR in the environment at the national level.” This course builds on WHO’s 2024 Guidance on wastewater and solid waste management for manufacturing of antibiotics. For further reading, see also the 25 Sep 2023 newsletter entitled “Manufacturing underpins both access and stewardship: Cefiderocol as a case study” and the 28 Jan 2024 newsletter entitled “EMA Concept Paper: Guidance on manufacturing of phage products”.